Atu027 & gemcitabine in lead in safety period + Atu027 & gemcitabine in treatment arm 1 + Atu027 & gemcitabine in treatment arm 2
Phase 1/2Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Carcinoma, Pancreatic Ductal
Conditions
Carcinoma, Pancreatic Ductal
Trial Timeline
Mar 1, 2013 → Jan 1, 2016
NCT ID
NCT01808638About Atu027 & gemcitabine in lead in safety period + Atu027 & gemcitabine in treatment arm 1 + Atu027 & gemcitabine in treatment arm 2
Atu027 & gemcitabine in lead in safety period + Atu027 & gemcitabine in treatment arm 1 + Atu027 & gemcitabine in treatment arm 2 is a phase 1/2 stage product being developed by Silence Therapeutics for Carcinoma, Pancreatic Ductal. The current trial status is completed. This product is registered under clinical trial identifier NCT01808638. Target conditions include Carcinoma, Pancreatic Ductal.
Hype Score Breakdown
Clinical
13
Activity
8
Company
2
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01808638 | Phase 1/2 | Completed |
Competing Products
20 competing products in Carcinoma, Pancreatic Ductal